CAL-101 is under clinical development by Calluna Pharma and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase I drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAL-101 overview
CAL-101 is under development for the treatment of chronic plaque psoriasis, fibrosis and inflammation indications. It is administered through intravenous route. The drug candidate is a monoclonal antibody which acts by targeting S100A4.
The drug candidate was under development for the treatment of metastatic cancer, mammary tumor with metastasis to the lung and systemic sclerosis
Calluna Pharma overview
Calluna Pharma is a biotechnology company engaged in research and developing novel therapeutics for the treatment of chronic inflammation and fibrosis. The company is headquartered in Oslo City, Oslo, Norway.
For a complete picture of CAL-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
